Eylea: Contra-indicated in patients with ocular or periocular infection or active intraocular inflammation.
Aflibercept-jbvf (Yesafili) is biosimilar to Aflibercept (Eylea). Approved 05/20/2024
Aflibercept-yszy (Opuviz) is biosimilar to Aflibercept (Eylea). Approved 05/20/2024
Aflibercept-mrbb (Ahzantive) is biosimilar to Aflibercept (Eylea). Approved 06/28/2024
- TRADE NAMES: Eylea (Regeneron); Zaltrap (Sanofi-Aventis)
- INDICATIONS: Neovascular (wet) age-related macular degeneration (Eylea); metastatic colorectal cancer (Zaltrap) in combination with FOLFIRI (fluorouracil, leucovorin and irinotecan)
- SYNONYM: ziv-aflibercept
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, Fusion protein
- HALF-LIFE: terminal 5–6 days
- FDA APPROVAL DATE: 08/03/2012
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
Zaltrap: HEMORRHAGE, GASTROINTESTINAL PERFORATION, COMPROMISED WOUND HEALING
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.
Page last updated 07/17/2024
